Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05448443
Other study ID # 09J201
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date June 21, 2022
Est. completion date April 30, 2025

Study information

Verified date June 2024
Source Istituto Auxologico Italiano
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double blind, placebo-controlled, cross-over, phase II, single center efficacy study of AD981 in patients with obesity hypoventilation syndrome documented by polysomnography (PSG) and transcutaneous, overnight measurement of CO2 (PtcCO2).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 15
Est. completion date April 30, 2025
Est. primary completion date May 15, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Be able to understand the nature of the study and sign the informed consent - BMI > 35 kg/m2 and presence of nocturnal hypoventilation - Previous surgical treatment for OSA is allowed if = 1 year prior to enrollment - If in treatment, CPAP or BPAP or mandibular advancement device or positional therapy intolerance or poor compliance Exclusion Criteria: - Narcolepsy, craniofacial malformation, renal failure, hepatic disease, schizophrenia, schizoaffective disorder or bipolar disorder, cognitive dysfunction, severe neurological disorder, pheochromocytoma, adrenocortical insufficiency, hyperchloremic acidosis. - Respiratory (COPD, ILD, oxygen therapy) or cardiac (Heart Failure, Atrial fibrillation, established severe peripheral arterial disease) disease or hypertension requiring more than 3 medications for control - Cardiomyopathies, heart malformation or structural heart alterations, severe rhythm disorders, established coronary heart disease or other cardiac conditions, which could determine sudden death - Attempted suicide or suicidal ideation - Drugs of abuse or substance use disorder - A significant illness or infection requiring medical treatment in the past 30 days. - Untreated narrow angle glaucoma. - Women who are pregnant or nursing. - Treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors, or monoamine oxidase inhibitors (MAOI) or linezolid within 14 days of the start of treatment, allergies to sulfonamides. - Diabetes with unstable glucose control in the past 15 days. - > 500 mg/day of Aspirin - Low sodium or potassium. - Any condition that in the investigator's opinion would present an unreasonable risk to the participant. - History of using oral or nasal devices (such as mandibular advancement devices) for the treatment of OSA may enroll as long as the devices are not used during participation in the study for at least 2 weeks prior to study begin. - History of using devices to affect participant sleeping position for the treatment of OSA, e.g. to discourage supine sleeping position, may enroll as long as the devices are not used during participation in the study. - Use of another investigational agent within 30 days or 5 half-lives, whichever is longer, prior to dosing. - Patient currently receiving: MAOIs, Serotonin and Norepinephrine Reuptake Inhibitors, Norepinephrine Reuptake Inhibitors, Lithium, Tricyclic antidepressants, strong CYP2D6 inhibitors, other strong inhibitors cytochrome P450, thiazides diuretics, benzodiazepines, opioids, drugs with clinically significant cardiac QT-interval prolonging effects, drugs known to lower seizure threshold, amphetamines, antiepileptics, modafinil or armodafinil, beta2 agonists, antipsychotics, pseudoephedrine, phenylephrine, oxymetazoline, drugs for Parkinson's, Alzheimer's, Huntington's, Amyotrophic Lateral Sclerosis, or drugs for other neurodegenerative diseases, more than 500 mg/day of Aspirin or salicylates, sodium Phosphate. - Known hypersensitivity to study drugs

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AD981
Oral administration of AD981 in the morning and before sleep for 14 days
Other:
Placebo
Oral administration of placebo in the morning and before sleep for 14 days

Locations

Country Name City State
Italy Istituto Auxologico Italiano,Ospedale San Luca Milano

Sponsors (5)

Lead Sponsor Collaborator
Istituto Auxologico Italiano Apnimed Inc., STM Pharma PRO srl, University of Florence, VIS Ethic Research Srl

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Nocturnal transcutaneous CO2 pressure (PtcCO2) From baseline to the last day of treatment (14 days after the start of each treatment period)
Secondary Proportion of participants without nocturnal hypoventilation From baseline to the last day of treatment (14 days after the start of each treatment period)
Secondary Apnea-Hypopnea Index (AHI) From baseline to the last day of treatment (14 days after the start of each treatment period)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06367686 - Detecting Systemic Carbon Dioxide Levels With a Novel Biosensor
Completed NCT06442163 - Average Volume-assured Pressure Support as Rescue Therapy in Obesity Hypoventilation Syndrome N/A
Not yet recruiting NCT05805293 - HVNI Versus NIV In Management Of Acute Hypercapnic Respiratory Failure In OHS N/A
Active, not recruiting NCT05167201 - Domiciliary Nasal High Flow and Patient Outcomes in Chronic Hypercapnic Respiratory Failure in the United Kingdom N/A
Completed NCT04884165 - Remote Monitoring to Improve Low Adherence in Non-invasive Ventilation N/A
Recruiting NCT06090149 - Telemedical Assistance in Automatic Titration of Oxygen for Intensive Care Patients N/A
Recruiting NCT04025528 - Pathophysiology of Hypoventilation in Obesity and Effects of Bariatric Intervention
Recruiting NCT04688125 - Evaluation of An Optical Measurement Algorithm Combined With Patient and Provider Input to Reduce Mask Exchanges During Initial Positive Airway Pressure Therapy
Recruiting NCT05398068 - Effects of Exercise Training on Exercise Capacity and Sleep Quality in Patients With Obesity Hypoventilation Syndrome N/A
Withdrawn NCT04317326 - "Post-acute Pickwick Study" (Postacute-Pick-2020) N/A
Completed NCT04615078 - Study Evaluating Telemonitoring and Experimentation in Telemedicine for the Improvement of Healthcare Pathways (ETAPES Program) Compared to Standard of Care in Patients With Chronic Respiratory Failure Receiving Non-invasive Home Ventilation N/A
Completed NCT04835558 - Respiratory Muscle Endurance in Obesity Hypoventilation Syndrome
Completed NCT04570540 - Obesity in Sleep Medicine - Focusing on OHS Phenotypes
Not yet recruiting NCT06136533 - The Effect of Sarcopenic Obesity on Sleep in Individuals With Obesity Hypoventilation Syndrome
Withdrawn NCT01991535 - Response to NonInvasive Mechanical Ventilation According to the Breathing Pattern N/A